All In Biotech

Drug Trial Radar · NCT05052255

RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors

An Open-label, Single Agent, Phase I/II Trial Investigating the Safety and Efficacy of RVU120 (SEL120) in Patients With Relapse / Refractory Metastatic or Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

66

Actual

Start

Aug 13, 2021

Primary completion

Oct 2, 2025

Study completion Oct 2, 2025

Sponsor

Lead sponsor
Ryvu Therapeutics SAIndustry
Sponsor type
Industry
First posted
Sep 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/2, dose-escalation and expansion study investigating the safety, pharmacokinetics, and efficacy of RVU120 (SEL120) in patients with metastatic or advanced solid tumors progressing from previous lines of therapy.

Conditions

  • Advanced Solid Tumor

Interventions

  • RVU120Drug

    RVU120 will be administered as a single oral dose every other day over a 3 week treatment cycle until disease progression or unacceptable toxicity and an alternative daily dosing schedule will also be tested.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events in part ITime frame: Up to 2 years
  2. Dose Finding in part ITime frame: Up to 2 years
  3. Objective Overall Response in part IITime frame: Up to 2 years
  4. Duration of Response in part IITime frame: Up to 2 years
  5. Progression Free Survival in part IITime frame: Up to 2 years
  6. Overall Survival in part IITime frame: Up to 2 years

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Beskidzkie Centrum Onkologii, Szpital Miejski im.

    Bielsko-Biala, Poland

  • Medical University Early Phase 1 Research Center / Uniwersyteckie Centrum Kliniczne Ośrodek Badań Klinicznych Wczesnych Faz

    Gdansk, Poland

  • UCK im. prof. K. Gibińskiego

    Katowice, Poland

  • Maria Sklodowska-Curie National Research Institute of Oncology / Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy

    Warsaw, Poland

  • Next Oncology Hospital Quironsalud Barcelona

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Next Oncology Hospital Universitario Quironsalud Madrid

    Pozuelo de Alarcón, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.